Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

5.90USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$5.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
417,523
52-wk High
$27.00
52-wk Low
$5.81

Chart for

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $371.64
Shares Outstanding(Mil.): 62.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Armistice Capital LLC reports 6.4 pct passive stake in Depomed Inc

* Armistice Capital LLC reports 6.4 percent passive stake in Depomed Inc as on August 8, 2017 - SEC filing‍​‍​ Source text (http://bit.ly/2vLa8Uq) Further company coverage:

Aug 18 2017

BRIEF-Depomed Q2 loss per share $0.43

* Q2 earnings per share view $0.09 -- Thomson Reuters I/B/E/S

Aug 07 2017

BRIEF-Depomed announces intent to effect a debt refinancing

* Seeking to refinance its existing $375 million principal amount of privately placed secured senior notes

Jul 13 2017

BRIEF-Depomed chief medical officer Srinivas Rao resigns

* Depomed inc - on june 30, co entered agreement with Srinivas G. Rao, co's chief medical officer, pursuant to which dr. Rao to resign as officer of co Source text for Eikon: Further company coverage:

Jul 07 2017

BRIEF-Depomed announces corporate governance updates

* Depomed - revised each of charters of audit committee, compensation committee, nominating and corporate governance committee

May 22 2017

BRIEF-Depomed reports Q1 adjusted non-GAAP earnings $0.07/shr

* Depomed announces first quarter 2017 financial results and strategic initiatives aimed at driving sustainable long-term growth and shareholder value

May 09 2017

BRIEF-Depomed announces prepayment of $100 mln of secured debt facility

* Depomed announces prepayment of $100 million of secured debt facility

Apr 04 2017

BRIEF-Depomed- Cooperation agreement with Starboard Value LP includes standstill commitments by Starboard

* Depomed- cooperation agreement with Starboard Value LP includes standstill commitments by Starboard

Mar 29 2017

U.S. senator launches probe into five top opioid drugmakers

U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation's top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country's deadly opioid crisis.

Mar 28 2017

Depomed names new CEO, directors in deal with activist Starboard

Depomed Inc reached a deal with activist investor Starboard Value LP to name a new chief executive officer and two other directors to its board.

Mar 28 2017

Earnings vs. Estimates